Therefore, PLOD2 may be a potential therapeutic target of breast cancer, since impeding PLOD2 is able to directly inhibit cancer cell migration and indirectly block the role of stromal cell-derived collagen reorganization. Here, PLOD2 is linked to breast carcinoma.